These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 8630918)

  • 1. Survival of women with advanced ovarian cancer and complete pathologic response at second-look laparotomy.
    Bolis G; Villa A; Guarnerio P; Ferraris C; Gavoni N; Giardina G; Melpignano M; Scarfone G; Zanaboni F; Parazzini F
    Cancer; 1996 Jan; 77(1):128-31. PubMed ID: 8630918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term survival of 106 stage III ovarian cancer patients with minimal residual disease after second-look laparotomy and consolidation radiotherapy.
    Petit T; Velten M; d'Hombres A; Marchal C; Montbarbon X; Mornex F; Quetin P; Gérard JP; Romestaing P; Carrie C
    Gynecol Oncol; 2007 Jan; 104(1):104-8. PubMed ID: 16987544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgical cytoreduction during second-look laparotomy in patients with advanced ovarian cancer.
    Gadducci A; Iacconi P; Fanucchi A; Cosio S; Teti G; Genazzani AR
    Anticancer Res; 2000; 20(3B):1959-64. PubMed ID: 10928134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of treatment failures and survival of patients with fallopian tube carcinoma: a cooperation task force (CTF) study.
    Gadducci A; Landoni F; Sartori E; Maggino T; Zola P; Gabriele A; Rossi R; Cosio S; Fanucchi A; Tisi G
    Gynecol Oncol; 2001 May; 81(2):150-9. PubMed ID: 11330942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment.
    Del Campo JM; Felip E; Rubio D; Vidal R; Bermejo B; Colomer R; Zanon V
    Gynecol Oncol; 1994 Apr; 53(1):27-32. PubMed ID: 8175018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
    Wimberger P; Lehmann N; Kimmig R; Burges A; Meier W; Du Bois A;
    Gynecol Oncol; 2007 Jul; 106(1):69-74. PubMed ID: 17397910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
    Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma.
    Tournigand C; Louvet C; Molitor JL; Dehni N; Lejeune V; Sezeur A; Pigne A; Marpeau L; Cady J; de Gramont A
    Gynecol Oncol; 2001 Nov; 83(2):198-204. PubMed ID: 11606072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of failures after negative second-look in patients with advanced ovarian cancer: an Italian multicenter study.
    Gadducci A; Sartori E; Maggino T; Zola P; Landoni F; Fanucchi A; Palai N; Alessi C; Ferrero AM; Cosio S; Cristofani R
    Gynecol Oncol; 1998 Feb; 68(2):150-5. PubMed ID: 9514797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [10 Year follow up of chemotherapy and surgery on the second laparotomy in advanced ovarian cancer].
    Ojeda B; Llanos M; Brunet J; Lacasta A; Alonso MC; Rueda A; Delgado E; Badía J; López López JJ
    Med Clin (Barc); 1995 Feb; 104(5):165-9. PubMed ID: 7877374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival and prognostic factors of women with advanced ovarian cancer and complete response after a carboplatin-paclitaxel chemotherapy.
    Polverino G; Parazzini F; Stellato G; Scarfone G; Cipriani S; Bolis G
    Gynecol Oncol; 2005 Nov; 99(2):343-7. PubMed ID: 16051334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second-look laparotomy in stage III epithelial ovarian cancer: clinical variables associated with disease status.
    Berek JS; Hacker NF; Lagasse LD; Poth T; Resnick B; Nieberg RK
    Obstet Gynecol; 1984 Aug; 64(2):207-12. PubMed ID: 6539884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose melphalan-based chemotherapy and autologous stem cell transplantation after second look laparotomy in patients with chemosensitive advanced ovarian carcinoma: long-term results.
    Bertucci F; Viens P; Delpero JR; Bardou VJ; Faucher C; Houvenaeghel G; Maraninchi D
    Bone Marrow Transplant; 2000 Jul; 26(1):61-7. PubMed ID: 10918406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
    Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
    Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Negative second-look laparatomy in ovarian cancers. Survival analysis and prognostic factors from 64 cases treated at the Gustave Roussy Institute].
    Pautier P; Rey A; Michel G; Castaigne D; Rochard F; Duvillard P; Haie-Meder C; Curcio P; Benedetti-Richard L; Lhommé C
    Bull Cancer; 1997 Feb; 84(2):147-54. PubMed ID: 9180837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gynecological malignancies.
    Schaebler DL; Schilder RJ; Young RC
    Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
    Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
    Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between time interval from primary surgery to the start of taxane- plus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: results of a multicenter retrospective Italian study.
    Gadducci A; Sartori E; Landoni F; Zola P; Maggino T; Maggioni A; Cosio S; Frassi E; LaPresa MT; Fuso L; Cristofani R
    J Clin Oncol; 2005 Feb; 23(4):751-8. PubMed ID: 15613698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.